NVCR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NV

Mkt Cap

$1.64B

Volume

1.01M

Next Earnings

October 29th

Loading chart

NV

NVCRNovoCure Limited Ordinary Shares

NVCR

Pay with—

Available Balance0.00

NV

Mkt Cap

$1.64B

Volume

1.01M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Novocure Reports Patient Data Exposure in Cybersecurity IncidentNovocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.Zacks Investment Research · Sep 7, 2026

Stock Market Today, June 4: Broadcom Drags on Nasdaq at MiddayBroadcom's disappointing AI-chip guidance triggered a semiconductor sell-off, dragging down the Nasdaq while the S&P 500 and Dow Jones gained on sector rotation and value tailwinds. Healthcare stocks rallied with Eli Lilly and NovoCure posting strong gains. The pullback raises questions about AI stock valuations and whether the semiconductor sector's 170% annual rally is cooling.The Motley Fool · Jun 4, 2026

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsightThe glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.GlobeNewswire Inc. · May 27, 2026

New Treatment Modalities Are Reaching Cancers That Resisted Everything ElseSeveral biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.Benzinga · Feb 17, 2026

Soleus Adds a Significant Number of Celcuity SharesSoleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.The Motley Fool · Feb 13, 2026

FDA Approves First-of-Its-Kind Device to Treat Pancreatic CancerThe FDA has approved Optune Pax, a portable non-invasive device developed by Novocure that delivers tumor treating fields (TTFields) to treat locally advanced pancreatic cancer. The device, which received Breakthrough Device designation, showed approximately two months improvement in overall survival when combined with standard chemotherapy in clinical trials.GlobeNewswire Inc. · Feb 12, 2026

Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED)U.S. stock futures rose on Thursday following a strong January jobs report showing 130,000 jobs added, exceeding expectations. The report dampened rate cut expectations, with markets pricing in only a 6% chance of a March rate cut. Key movers include Micron (up 3.3%), Novocure (up 33% on FDA approval), and Fastly (up 43% on strong earnings), while AppLovin fell 4.95% despite beating expectations.Benzinga · Feb 12, 2026

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual MeetingNovocure announced positive results from its Phase 3 METIS trial, demonstrating that Tumor Treating Fields (TTFields) therapy can significantly delay brain metastasis progression in non-small cell lung cancer patients without causing neurocognitive side effects.Benzinga · Sep 29, 2025

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street AnalystsWall Street analysts are bullish on Viking Therapeutics and NovoCure, two healthcare stocks with significant potential growth despite recent market challenges in their clinical trials and product launches.The Motley Fool · Aug 29, 2025

Novocure: Steady Ahead of Key MilestonesNovocure reported 6% revenue growth and 9% patient growth, with plans to seek FDA approval for pancreatic and brain cancer treatments. Despite not being profitable, the company maintains significant cash reserves and potential for future development.The Motley Fool · Jul 24, 2025

to start trading

NV

NVCRNovoCure Limited Ordinary Shares

NVCR

Pay with—

Available Balance0.00

Your PositionYou don't own any NVCR yet.

Related Tickers

Earnings